Abstract
Sulfonylureas (SU) are one of the most used antidiabetic medications mainly due to their cost-effectiveness and reduced frequency of dosing. They have a therapeutic effect in patients with adequate β cell function. SU were rst discovered in 1942 by Janbon who observedthat some sulfonamides generated hypoglycemia in experimental animals. Carbutamide wasthe rst sulfonylurea which was discovered and used to treat diabetes, but was subsequentlywithdrawn from the market because of damage to the bone marrow. By the 1960s several SU became available; they were classied into 2 generations. Gliclazide, Glipizide, Glibenclamideand Glimepiride are second-generation sulfonylureas, currently used, while rst-generation drugs
(such as Tolbutamide and Chlorpropamide) are no longer used due to their adverse cardiovascular prole. Second generation drugs are as effective as rst-generation drugs to lower the blood glucose concentrations, but there are differences in absorption, metabolism and dosing
(such as Tolbutamide and Chlorpropamide) are no longer used due to their adverse cardiovascular prole. Second generation drugs are as effective as rst-generation drugs to lower the blood glucose concentrations, but there are differences in absorption, metabolism and dosing
Original language | English |
---|---|
Title of host publication | Current Status of Sulphonylureas afterCAROLINA and CARMELINA Trial -Maximum Glycemic Efficacy with CardiacSafety |
Publisher | Microlabs DTF |
Chapter | 10 |
Pages | 70-76 |
Number of pages | 6 |
Publication status | Published - 09-2022 |